稀有生物標記檢體採集與穩定化市場：規模、佔有率及成長分析（按產品類型、生物標記類型、應用、檢體類型、最終用戶和地區分類）－產業預測，2026-2033年

2024 年全球罕見生物標記檢體採集和穩定市場價值為 397 億美元，預計到 2025 年將成長至 452.2 億美元，到 2033 年將成長至 1280.9 億美元，在預測期（2026-2033 年）內複合年成長率為 13.9%。

受精準醫療和液態生物檢體對高精度檢體日益成長的需求驅動，全球稀有生物標記檢體採集和穩定化市場正迅速擴張。此領域涵蓋專用採集設備、創新穩定化學物質以及物流系統，旨在維持循環腫瘤DNA和外泌體等脆弱分析物的完整性。由於採集檢體的品質對檢測靈敏度至關重要，生物樣本庫和臨床檢查室正在尋求減少檢體劣化的解決方案。從標準真空幫浦到先進的cfDNA和RNA儲存管的轉變，反映了室溫儲存日益普及的趨勢，尤其是在癌症和懷孕檢測領域。此外，新的儲存技術正在改變分散式臨床試驗和家庭監測，製藥公司也正在採用穩定化檢體工作流程，以提高生物標記主導研究中的數據品質和保存率。

全球罕見生物標記檢體採集與穩定市場促進因素

隨著精準診斷的日益普及，對稀有生物標記檢體採集和穩定化解決方案的需求正在推動市場成長。這是因為可靠的檢體檢驗低濃度分析物、驗證新型生物標記物以及促進標靶治療至關重要。臨床研究人員和診斷開發人員正在尋求一致的檢體採集和儲存方法，以確保不同機構和檢查室的檢體完整性。這使得對特定檢體的檢測無論在何處進行都能獲得一致的結果。診斷需求與有效檢體管理的這種契合正在推動市場成長，促進了能夠最大限度減少分析前變異性的技術的應用，從而支持轉化研究和臨床檢驗工作。

全球稀有生物標記檢體採集和穩定化市場面臨的限制因素

檢體採集設備和穩定劑相關法規的多樣性和複雜性給製造商帶來了巨大挑戰。這種不一致會導致不同地區核准流程和可接受效能標準的差異，進而造成混亂。因此，製造商和創新者往往面臨產品在臨床應用中長期落後的困境。由於安全性和性能標準的合規性至關重要，且各司法管轄區的標準差異顯著，這些監管障礙可能會阻礙潛在買家，延長市場擴張的時間，並使罕見生物標記檢體採集的市場格局更加複雜。

全球稀有生物標記檢體採集和穩定化市場趨勢。

受多組體學整合解決方案需求的不斷成長的推動，全球罕見生物標記檢體採集和穩定化市場呈現顯著成長態勢。隨著研究人員日益關注如何維護涵蓋基因組學、轉錄組學、蛋白質組學和代謝體學等多種生物檢體的完整性，製造商正在開發標準化的採集方案和創新的穩定化技術。這一趨勢旨在促進生物樣本庫、臨床中心和診斷設備製造商之間的合作，最大限度地減少檢體浪費，並加速生物標記的檢驗過程。對多組體學整合的重視增強了各種下游平台和分析方法之間的兼容性，最終提高了全球研究人群的可重複性和可靠性。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球罕見生物標記檢體採集和穩定化市場規模：按產品類型分類

• 採血管
  • cfDNA穩定管
  • CTC 儲存管
  • RNA穩定管
  • 多參數穩定管
  • 其他
• 檢體採集工具包
  • 液態生物檢體採集試劑盒
  • 基因組樣本採集試劑盒
  • 腫瘤生物標記採集試劑盒
  • 產前檢測檢體套裝
  • 感染疾病標記檢測試劑盒
  • 其他
• 穩定劑和防腐劑
  • DNA穩定劑
  • RNA穩定劑
  • 蛋白質穩定劑
  • 細胞保存試劑
  • 其他
• 檢體運送和儲存解決方案
  • 低溫儲存系統
  • 溫控運輸解決方案
  • 生物銀行耗材
  • 其他

全球罕見生物標記檢體採集和穩定化市場規模：按生物標記類型分類

• 循環性腫瘤細胞（CTCs）
• 無細胞DNA（cfDNA）
• 無細胞RNA（cfRNA）
• 細胞外囊泡和外泌體
• 蛋白質體學生物標記
• 稀有細胞生物標記物
• 其他

全球稀有生物標記檢體採集和穩定化市場規模：按應用領域分類。

• 腫瘤診斷
• 非侵入性產前檢測（NIPT）
• 傳染病檢查
• 移植監測
• 精準醫療和伴隨診斷
• 臨床研究和生物銀行
• 其他

全球罕見生物標記檢體採集和穩定化市場規模：按樣本類型分類

• 血液檢體
• 血漿和血清樣本
• 尿液檢體
• 唾液樣本
• 組織樣本
• 其他

全球罕見生物標記檢體採集和穩定化市場規模：按最終用戶分類

• 醫院/診斷檢查室
• 學術研究機構
• 生物製藥和生物技術公司
• 受託研究機構（CRO）
• 其他

全球罕見生物標記檢體採集和穩定化市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• QIAGEN NV
• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories, Inc.
• Becton, Dickinson and Company
• Illumina, Inc.
• Exact Sciences Corporation
• Natera, Inc.
• Guardant Health, Inc.
• Streck, Inc.
• Menarini Silicon Biosystems
• Biocept, Inc.
• Angle plc
• Miltenyi Biotec BV & Co. KG
• Sysmex Corporation
• Greiner Bio-One International GmbH
• PreAnalytiX GmbH
• DNA Genotek Inc.
• Cynvenio Biosystems, Inc.
• Fluxion Biosciences, Inc.

結論與建議

Global Rare Biomarkers Specimen Collection And Stabilization Market size was valued at USD 39.7 Billion in 2024 and is poised to grow from USD 45.22 Billion in 2025 to USD 128.09 Billion by 2033, growing at a CAGR of 13.9% during the forecast period (2026-2033).

The global rare biomarkers specimen collection and stabilization market is rapidly advancing, fueled by an increasing need for precise samples essential for precision medicine and liquid biopsies. This sector encompasses specialized collection devices, innovative stabilizing chemistries, and logistics systems that maintain the integrity of delicate analytes like circular tumor DNA and exosomes. The quality of collected samples critically impacts assay sensitivity, prompting biobanks and clinical laboratories to seek solutions that mitigate sample degradation. The shift from standard vacutainers to advanced cfDNA and RNA-preservation tubes reflects a growing trend towards ambient temperature preservation, particularly in cancer and pregnancy tests. Moreover, novel preservation technologies are transforming decentralized clinical trials and home monitoring, with pharmaceutical companies embracing stabilized specimen workflows to enhance data quality and retention in biomarker-driven studies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Rare Biomarkers Specimen Collection And Stabilization market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Rare Biomarkers Specimen Collection And Stabilization Market Segments Analysis

Global rare biomarkers specimen collection and stabilization market is segmented by product type, biomarker type, application, sample type, end user and region. Based on product type, the market is segmented into blood collection tubes, specimen collection kits, stabilization reagents & preservatives and specimen transport & storage solutions. Based on biomarker type, the market is segmented into circulating tumor cells (CTCs), cell-free DNA (cfDNA), cell-free RNA (cfRNA), extracellular vesicles & exosomes, proteomic biomarkers, rare cell biomarkers and others. Based on application, the market is segmented into oncology diagnostics, non-invasive prenatal testing (nipt), infectious disease testing, transplant monitoring, precision medicine & companion diagnostics, clinical research & biobanking and others. Based on sample type, the market is segmented into blood samples, plasma & serum samples, urine samples, saliva samples, tissue samples and others. Based on end user, the market is segmented into hospitals & diagnostic laboratories, academic & research institutes, biopharmaceutical & biotechnology companies, contract research organizations (CROs) and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Rare Biomarkers Specimen Collection And Stabilization Market

The rising emphasis on precision diagnostics drives demand for rare biomarker specimen collection and stabilization solutions, as reliable specimens are crucial for identifying low-abundance analytes, validating novel biomarkers, and facilitating targeted therapies. Clinical researchers and diagnostic developers seek consistent specimen collection and preservation methods to ensure integrity across various sites and laboratories, allowing assays performed on a particular specimen to yield uniform results regardless of the testing location. This alignment between diagnostic needs and effective specimen management fosters market growth by promoting the adoption of technologies that minimize preanalytical variability, thus supporting translational and clinical validation efforts.

Restraints in the Global Rare Biomarkers Specimen Collection And Stabilization Market

The complexity of varying regulations concerning specimen collection devices and stabilizing agents poses significant challenges for manufacturers. This inconsistency can create confusion around the required approval processes and acceptable performance standards across different regions. As a result, manufacturers and innovators often face prolonged delays in the introduction and acceptance of their products in clinical settings. Such regulatory hurdles can lead to hesitation among potential purchasers and extend the timeline for market expansion, as adherence to safety and performance standards is critical and varies widely across jurisdictions, complicating the overall market landscape for rare biomarker specimen collection.

Market Trends of the Global Rare Biomarkers Specimen Collection And Stabilization Market

The Global Rare Biomarkers Specimen Collection and Stabilization market is witnessing a significant upward trend, driven by the growing demand for multi-omics integrative solutions. As researchers increasingly focus on preserving the integrity of diverse biological samples across genomics, transcriptomics, proteomics, and metabolomics, manufacturers are developing standardized collection protocols and innovative stabilizing chemistries. This alignment fosters collaborative efforts among biobanks, clinical sites, and diagnostic manufacturers, aiming to minimize sample waste and expedite biomarker validation processes. The emphasis on multi-omic integration enhances compatibility across various downstream platforms and analytics, ultimately improving reproducibility and reliability among study populations on a global scale.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Rare Biomarkers Specimen Collection And Stabilization Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Blood Collection Tubes
  • cfDNA Stabilization Tubes
  • CTC Preservation Tubes
  • RNA Stabilization Tubes
  • Multi-Analyte Stabilization Tubes
  • Others
• Specimen Collection Kits
  • Liquid Biopsy Collection Kits
  • Genomic Sample Collection Kits
  • Oncology Biomarker Collection Kits
  • Prenatal Testing Collection Kits
  • Infectious Disease Biomarker Kits
  • Others
• Stabilization Reagents & Preservatives
  • DNA Stabilization Reagents
  • RNA Stabilization Reagents
  • Protein Stabilization Reagents
  • Cell Preservation Reagents
  • Others
• Specimen Transport & Storage Solutions
  • Cryogenic Storage Systems
  • Temperature-Controlled Transport Solutions
  • Biobanking Consumables
  • Others

Global Rare Biomarkers Specimen Collection And Stabilization Market Size by Biomarker Type & CAGR (2026-2033)

• Market Overview
• Circulating Tumor Cells (CTCs)
• Cell-Free DNA (cfDNA)
• Cell-Free RNA (cfRNA)
• Extracellular Vesicles & Exosomes
• Proteomic Biomarkers
• Rare Cell Biomarkers
• Others

Global Rare Biomarkers Specimen Collection And Stabilization Market Size by Application & CAGR (2026-2033)

• Market Overview
• Oncology Diagnostics
• Non-Invasive Prenatal Testing (NIPT)
• Infectious Disease Testing
• Transplant Monitoring
• Precision Medicine & Companion Diagnostics
• Clinical Research & Biobanking
• Others

Global Rare Biomarkers Specimen Collection And Stabilization Market Size by Sample Type & CAGR (2026-2033)

• Market Overview
• Blood Samples
• Plasma & Serum Samples
• Urine Samples
• Saliva Samples
• Tissue Samples
• Others

Global Rare Biomarkers Specimen Collection And Stabilization Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals & Diagnostic Laboratories
• Academic & Research Institutes
• Biopharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)
• Others

Global Rare Biomarkers Specimen Collection And Stabilization Market Size & CAGR (2026-2033)

• North America (Product Type, Biomarker Type, Application, Sample Type, End User)
  • US
  • Canada
• Europe (Product Type, Biomarker Type, Application, Sample Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Biomarker Type, Application, Sample Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Biomarker Type, Application, Sample Type, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Biomarker Type, Application, Sample Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• QIAGEN N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natera, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Streck, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Menarini Silicon Biosystems
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocept, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Angle plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Miltenyi Biotec B.V. & Co. KG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Greiner Bio-One International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PreAnalytiX GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DNA Genotek Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cynvenio Biosystems, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fluxion Biosciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations